We have derived JAK2-V617F-dependent MPN cells to be resistant to JAK2 inhibition (also referred to as persistent cells) by chronic, dose-escalation exposure to ruxolitinib, as previously described [60]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.